View profile

FarmaKology Newsletter - Issue #28

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


February 1 · Issue #28 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “”, and happy to have you featured on our newsletter (+1950 Subscribers ) !

Today's Startup
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges!Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.
WPD Pharmaceuticals Inc., a clinical stage pharmaceutical company, provides this update on the completed acquisition of exclusive sublicenses for two drug candidates from Moleculin Biotech, Inc. a leading global pharmaceuticals company focused on the treatment of highly resistant cancers. The territory covered by the patents includes 30 countries in Europe and Asia, including Russia. 
To help people get rid of various fatal diseases, StemRx Bioscience Solutions Pvt. Ltd., in association with Amity Institute of Biotechnology, Navi Mumbai, organized a one day International seminar on how technologies like Tissue Nanotransfection, bone marrow transplant, organ transplant, and umbilical cord blood transplantation can change the future course of various diseases like cancer.
The clinical development of the drug, designed using AI drug discovery technology from the UK company Exscientia, will be carried out by Sumitomo Dainippon Pharma, Exscientia’s Japanese collaborator. The drug took just 12 months to get to phase I, whereas conventional techniques take around five years. 
Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has initiated a program to develop a coronavirus vaccine candidate based on its proprietary oral vaccine platform, VAAST. 
Research & Study
Vaccinating the World One Collaboration at a Time by GEN Podcasts | Free Listening on SoundCloud
Job Opportunities
Upcoming Events
How Biologic Medicines Are Made | How It's Made
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue